Cargando…
STAT-1 Knockout Mice as a Model for Wild-Type Sudan Virus (SUDV)
Currently there is no FDA-licensed vaccine or therapeutic against Sudan ebolavirus (SUDV) infections. The largest ever reported 2014–2016 West Africa outbreak, as well as the 2021 outbreak in the Democratic Republic of Congo, highlight the critical need for countermeasures against filovirus infectio...
Autores principales: | Escaffre, Olivier, Juelich, Terry L., Neef, Natasha, Massey, Shane, Smith, Jeanon, Brasel, Trevor, Smith, Jennifer K., Kalveram, Birte, Zhang, Lihong, Perez, David, Ikegami, Tetsuro, Freiberg, Alexander N., Comer, Jason E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8310124/ https://www.ncbi.nlm.nih.gov/pubmed/34372594 http://dx.doi.org/10.3390/v13071388 |
Ejemplares similares
-
Filovirus Virulence in Interferon α/β and γ Double Knockout Mice, and Treatment with Favipiravir
por: Comer, Jason E., et al.
Publicado: (2019) -
Tilorone-Dihydrochloride Protects against Rift Valley Fever Virus Infection and Disease in the Mouse Model
por: Johnson, Kendra N., et al.
Publicado: (2021) -
Favipiravir (T-705) protects against Nipah virus infection in the hamster model
por: Dawes, Brian E., et al.
Publicado: (2018) -
Evaluations of rationally designed rift valley fever vaccine candidate RVax-1 in mosquito and rodent models
por: Ikegami, Tetsuro, et al.
Publicado: (2022) -
The Susceptibility of BALB/c Mice to a Mouse-Adapted Ebola Virus Intravaginal Infection
por: Escaffre, Olivier, et al.
Publicado: (2023)